CD19 and acute lymphoblastic leukemia: The multicentric phase I/II clinical trial (NCT03389035) aimed to assess the safety and feasibility of infusing allogeneic CARCIK-CD19 in patients with Acute B Lymphoblastic Leukemia (B-ALL) relapsed after HSCT.